EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19

Darren M Roberts iD, Xin Liu, Suzanne L Parker, Andrew Burke, Jenny Peek, Jane E Carland, Bridin Murnion, Vincent Seah, Steven C Wallis, Chandra D Sumi, Saurabh Pandey, Hergen Buscher und 7 weitere

Clinical Pharmacokinetics · 2025-05 · 64 (5) · 743-756

DOI: 10.1007/s40262-025-01496-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Pharmacokinetics, online erschienen am 22.04.2025. Verfasst von Darren M Roberts und 18 weiteren Autor:innen. Beteiligte Einrichtung: The University of Queensland Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisba…. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, COVID-19 Drug Treatment, Antiviral Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, Queensland Health, Prince Charles Hospital Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives There are limited data testing whether the licensed dose of remdesivir and its active metabolite GS-441524 achieve target concentrations in hospitalised patients with confirmed severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of coronavirus disease-2019 (COVID-19). The objectives of this study were to describe the population pharmacokinetics of remdesivir and GS-441524 in hospitalised patients treated for COVID-19 and develop a model to inform dose optimisation in clinical use.

Methods

This was a prospective, open-labelled, multi-centre, observational study in four Australian hospitals in adults with confirmed SARS-CoV-2 infection. Patients were administered the licensed remdesivir dose. Remdesivir and GS-441524 concentrations were quantified in multiple plasma samples at different times in the dosing interval by ultra-high-performance liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). Patients were divided into two groups: pharmacokinetic model building and external validation. A population pharmacokinetic analysis was built using non-linear mixed-effects modelling. Monte Carlo simulations were performed to describe the impact of age, kidney function and dosing regimen on drug concentrations.

Results

In total, 33 patients were enrolled (median age 70 years, estimated glomerular filtration rate (eGFR) 80 mL/min/1.73 m 2 ). The pharmacokinetics for both compounds were adequately described by a two-compartment model (one compartment for each compound) with first-order elimination. Key covariates included in the final model were age and eGFR. GS-441524 plasma concentrations exceeded the lowest reported half-maximal effective concentration (EC 50 ) with the recommended dosage, and higher dosages exceeded the lowest reported 90%-effective concentration (EC 90 ).

Conclusions

The licensed remdesivir dose may achieve target concentrations of GS-441524, but higher dosages may optimise outcomes. Dose adjustments are guided primarily by kidney function.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAlanineCOVID-19 Drug TreatmentAntiviral AgentsModels, BiologicalHumansFemaleMaleAgedMiddle AgedProspective StudiesCOVID-19HospitalizationAged, 80 and overAdultSARS-CoV-2Monte Carlo MethodAustraliaGlomerular Filtration RateAdenosine

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral AgentsGS-441524Adenosine

Autor:innen und Institutionen

  • The University of Queensland Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia. 1darren1@gmail.com.
  • Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital Sydney, Darlinghurst, Australia. 1darren1@gmail.com.
  • School of Clinical Medicine, Faculty of Medicine and Health, St Vincent's Healthcare Clinical Campus, University of New South Wales, Sydney, Australia. 1darren1@gmail.com.
  • Drug Health Services, Edith Collins Centre, Royal Prince Alfred Hospital, Sydney, Australia. 1darren1@gmail.com.
  • The University of Queensland Centre for Clinical Research, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Brisbane, Australia.
  • Department of Infectious Diseases, The Prince Charles Hospital, Brisbane, Australia.

ORCID-Profile: Darren M Roberts

Förderung

  • National Health and Medical Research Council
  • Queensland Health
  • Prince Charles Hospital Foundation
  • Australian and New Zealand Society of Nephrology
  • The University of Queensland

Zitieren

APA

Roberts, D. M., Liu, X., Parker, S. L., Burke, A., Peek, J., Carland, J. E., Murnion, B., Seah, V., Wallis, S. C., Sumi, C. D., Pandey, S., Buscher, H., Byrne, A., Sandaradura, I., Bowen, D., Holz, S., Stewart, A. G., Hajkowicz, K. M., & Roberts, J. A. (2025). Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19. Clinical Pharmacokinetics, 64(5), 743-756. https://doi.org/10.1007/s40262-025-01496-2

Vancouver

Roberts DM, Liu X, Parker SL, Burke A, Peek J, Carland JE, et al. Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19. Clinical Pharmacokinetics. 2025;64(5):743-756. doi:10.1007/s40262-025-01496-2

BibTeX
@article{Roberts2025,
  author = {Roberts, Darren M and Liu, Xin and Parker, Suzanne L and Burke, Andrew and Peek, Jenny and Carland, Jane E and Murnion, Bridin and Seah, Vincent and Wallis, Steven C and Sumi, Chandra D and Pandey, Saurabh and Buscher, Hergen and Byrne, Anthony and Sandaradura, Indy and Bowen, David and Holz, Simon and Stewart, Adam G and Hajkowicz, Krispin M and Roberts, Jason A},
  title = {Population Pharmacokinetic Modelling of Remdesivir and Its Metabolite GS-441524 in Hospitalised Patients with COVID-19},
  journal = {Clinical Pharmacokinetics},
  year = {2025},
  volume = {64},
  number = {5},
  pages = {743--756},
  doi = {10.1007/s40262-025-01496-2}
}
Kostenlos starten →